For children younger than five years of age,
supplementing oral vaccine with a shot of inactivated poliovirus vaccine
substantially boosts intestinal immunity to the crippling poliovirus.
by John
Tyburski
Copyright © Daily
Digest News, KPR Media, LLC. All rights reserved.
Polio is
rarely considered among the general public in developed countries but until
poliovirus is eradicated, all children, regardless of where they reside, are at
risk. Recently, poliovirus exhibited resurgence in
the Middle East and Africa, prompting concern among public health officials who
warn of global susceptibility.
Today, oral
poliovirus vaccine (OPV) is given to children at risk for poliovirus infection
to prevent the disease. However, OPV is not 100 percent effective, and the
immunity it confers diminishes over time. Vaccinated children may become
infected with, and transmit, poliovirus.
Injecting
inactivated poliovirus vaccine (IPV) in an arm by itself does not protect a
child from contracting polio because the immunity must be induced in the
intestinal mucosa where poliovirus attacks. This is why OPV is more effective
and preferred.
According to
a new report published
on Jul. 11 in the journal The Lancet, however, IPV may still offer
a boost in protection to children when used in combination with OPV. Last
year, Indian and British scientists conducted an open-label, randomized
controlled trial in 450 children, ages one through four years from Vellore,
India.
All of the
children enrolled in the study had received OPV prior to enrollment. Half of
the children were randomly assigned to receive IPV while the other half
received nothing. A month later, all children were challenged with live OPV as
a simulation of infection. Their stools were tested for poliovirus serotypes 1
and 3.
Children who
received IPV and whose stools tested positive for serotypes 1 or 3 numbered 38
percent and 70 percent fewer, respectively, compared with children who did not
receive IPV.
“An
additional dose of the injected vaccine is more effective at boosting immunity
against infection than the oral vaccine alone,” says Nick Grassly, a professor
of vaccine epidemiology at Imperial and co-author on the report. “This implies
that the IPV could be used to boost immunity in people travelling from or to
polio-infected countries.”
No comments:
Post a Comment